- Home
- REFI vs ZURA Comparison
REFI vs ZURA Comparison
Compare REFI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- ZURA
- Stock Information
- Founded
- REFI 2021
- ZURA 2022
- Country
- REFI United States
- ZURA United States
- Employees
- REFI N/A
- ZURA N/A
- Industry
- REFI Real Estate Investment Trusts
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REFI Real Estate
- ZURA Health Care
- Exchange
- REFI Nasdaq
- ZURA Nasdaq
- Market Cap
- REFI 304.4M
- ZURA 69.9M
- IPO Year
- REFI 2021
- ZURA N/A
- Fundamental
- Price
- REFI $13.97
- ZURA $1.05
- Analyst Decision
- REFI Strong Buy
- ZURA Buy
- Analyst Count
- REFI 3
- ZURA 7
- Target Price
- REFI $20.00
- ZURA $14.33
- AVG Volume (30 Days)
- REFI 105.2K
- ZURA 755.8K
- Earning Date
- REFI 08-06-2025
- ZURA 08-08-2025
- Dividend Yield
- REFI 13.46%
- ZURA N/A
- EPS Growth
- REFI N/A
- ZURA N/A
- EPS
- REFI 1.88
- ZURA N/A
- Revenue
- REFI $56,790,054.00
- ZURA N/A
- Revenue This Year
- REFI $15.53
- ZURA N/A
- Revenue Next Year
- REFI $6.70
- ZURA N/A
- P/E Ratio
- REFI $7.43
- ZURA N/A
- Revenue Growth
- REFI 4.68
- ZURA N/A
- 52 Week Low
- REFI $12.76
- ZURA $0.97
- 52 Week High
- REFI $16.47
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- REFI 51.51
- ZURA 48.12
- Support Level
- REFI $14.13
- ZURA $1.10
- Resistance Level
- REFI $14.43
- ZURA $1.22
- Average True Range (ATR)
- REFI 0.25
- ZURA 0.09
- MACD
- REFI 0.02
- ZURA 0.00
- Stochastic Oscillator
- REFI 66.72
- ZURA 31.25
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.